Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Genome Resequencing of Laboratory Stocks of Burkholderia pseudomallei K96243.

Wagley S, Scott AE, Ireland PM, Prior JL, Atkins TP, Bancroft GJ, Studholme DJ, Titball RW.

Microbiol Resour Announc. 2019 Feb 28;8(9). pii: e01529-18. doi: 10.1128/MRA.01529-18. eCollection 2019 Feb.

2.

Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization.

Kewcharoenwong C, Prabowo SA, Bancroft GJ, Fletcher HA, Lertmemongkolchai G.

Front Immunol. 2018 Sep 19;9:2109. doi: 10.3389/fimmu.2018.02109. eCollection 2018.

3.

Inactivation of bpsl1039-1040 ATP-binding cassette transporter reduces intracellular survival in macrophages, biofilm formation and virulence in the murine model of Burkholderia pseudomallei infection.

Pinweha P, Pumirat P, Cuccui J, Jitprasutwit N, Muangsombut V, Srinon V, Boonyuen U, Thiennimitr P, Vattanaviboon P, Cia F, Willcocks S, Bancroft GJ, Wren BW, Korbsrisate S.

PLoS One. 2018 May 17;13(5):e0196202. doi: 10.1371/journal.pone.0196202. eCollection 2018.

4.

Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?

Titball RW, Burtnick MN, Bancroft GJ, Brett P.

Vaccine. 2017 Oct 20;35(44):5981-5989. doi: 10.1016/j.vaccine.2017.03.022. Epub 2017 Mar 21. Review.

5.

A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth.

Wagley S, Vanaporn M, Rinchai D, Conejero L, Lertmemongkolchai G, Bancroft GJ, Titball RW.

Microb Pathog. 2017 Jun;107:175-180. doi: 10.1016/j.micpath.2017.03.015. Epub 2017 Mar 18.

6.

Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei.

Kessler B, Rinchai D, Kewcharoenwong C, Nithichanon A, Biggart R, Hawrylowicz CM, Bancroft GJ, Lertmemongkolchai G.

Sci Rep. 2017 Feb 20;7:42791. doi: 10.1038/srep42791.

7.

Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.

Nithichanon A, Gourlay LJ, Bancroft GJ, Ato M, Takahashi Y, Lertmemongkolchai G.

Immunology. 2017 May;151(1):98-109. doi: 10.1111/imm.12709. Epub 2017 Feb 9.

8.

Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione.

Kewcharoenwong C, Rinchai D, Nithichanon A, Bancroft GJ, Ato M, Lertmemongkolchai G.

Sci Rep. 2016 Oct 7;6:34794. doi: 10.1038/srep34794.

9.

Differential Production of Type I IFN Determines the Reciprocal Levels of IL-10 and Proinflammatory Cytokines Produced by C57BL/6 and BALB/c Macrophages.

Howes A, Taubert C, Blankley S, Spink N, Wu X, Graham CM, Zhao J, Saraiva M, Ricciardi-Castagnoli P, Bancroft GJ, O'Garra A.

J Immunol. 2016 Oct 1;197(7):2838-53. doi: 10.4049/jimmunol.1501923. Epub 2016 Aug 22.

10.

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection.

Sayes F, Pawlik A, Frigui W, Gröschel MI, Crommelynck S, Fayolle C, Cia F, Bancroft GJ, Bottai D, Leclerc C, Brosch R, Majlessi L.

PLoS Pathog. 2016 Jul 28;12(7):e1005770. doi: 10.1371/journal.ppat.1005770. eCollection 2016 Jul.

11.

Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis.

Casey WT, Spink N, Cia F, Collins C, Romano M, Berisio R, Bancroft GJ, McClean S.

Vaccine. 2016 May 17;34(23):2616-21. doi: 10.1016/j.vaccine.2016.03.088. Epub 2016 Apr 16.

PMID:
27091689
12.

Characterization of New Virulence Factors Involved in the Intracellular Growth and Survival of Burkholderia pseudomallei.

Moule MG, Spink N, Willcocks S, Lim J, Guerra-Assunção JA, Cia F, Champion OL, Senior NJ, Atkins HS, Clark T, Bancroft GJ, Cuccui J, Wren BW.

Infect Immun. 2015 Dec 28;84(3):701-10. doi: 10.1128/IAI.01102-15.

13.

Burkholderia pseudomallei kynB plays a role in AQ production, biofilm formation, bacterial swarming and persistence.

Butt A, Halliday N, Williams P, Atkins HS, Bancroft GJ, Titball RW.

Res Microbiol. 2016 Apr;167(3):159-67. doi: 10.1016/j.resmic.2015.11.002. Epub 2015 Nov 30.

PMID:
26654915
14.

The Blood Transcriptome of Experimental Melioidosis Reflects Disease Severity and Shows Considerable Similarity with the Human Disease.

Conejero L, Potempa K, Graham CM, Spink N, Blankley S, Salguero FJ, Pankla-Sranujit R, Khaenam P, Banchereau JF, Pascual V, Chaussabel D, Lertmemongkolchai G, O'Garra A, Bancroft GJ.

J Immunol. 2015 Oct 1;195(7):3248-3261. doi: 10.4049/jimmunol.1500641. Epub 2015 Aug 26.

15.

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.

Bottai D, Frigui W, Clark S, Rayner E, Zelmer A, Andreu N, de Jonge MI, Bancroft GJ, Williams A, Brodin P, Brosch R.

Vaccine. 2015 May 28;33(23):2710-8. doi: 10.1016/j.vaccine.2015.03.083. Epub 2015 Apr 11.

PMID:
25869896
16.

Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions.

Buddhisa S, Rinchai D, Ato M, Bancroft GJ, Lertmemongkolchai G.

J Immunol. 2015 May 1;194(9):4413-21. doi: 10.4049/jimmunol.1402417. Epub 2015 Mar 23.

17.

Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis.

Sander P, Clark S, Petrera A, Vilaplana C, Meuli M, Selchow P, Zelmer A, Mohanan D, Andreu N, Rayner E, Dal Molin M, Bancroft GJ, Johansen P, Cardona PJ, Williams A, Böttger EC.

Vaccine. 2015 Mar 10;33(11):1353-9. doi: 10.1016/j.vaccine.2015.01.058. Epub 2015 Feb 2.

PMID:
25657094
18.

CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

Musson JA, Reynolds CJ, Rinchai D, Nithichanon A, Khaenam P, Favry E, Spink N, Chu KK, De Soyza A, Bancroft GJ, Lertmemongkolchai G, Maillere B, Boyton RJ, Altmann DM, Robinson JH.

J Immunol. 2014 Dec 15;193(12):6041-9. doi: 10.4049/jimmunol.1402273. Epub 2014 Nov 12.

19.

Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection.

Kewcharoenwong C, Rinchai D, Utispan K, Suwannasaen D, Bancroft GJ, Ato M, Lertmemongkolchai G.

Sci Rep. 2013 Nov 28;3:3363. doi: 10.1038/srep03363.

20.

The condition-dependent transcriptional landscape of Burkholderia pseudomallei.

Ooi WF, Ong C, Nandi T, Kreisberg JF, Chua HH, Sun G, Chen Y, Mueller C, Conejero L, Eshaghi M, Ang RM, Liu J, Sobral BW, Korbsrisate S, Gan YH, Titball RW, Bancroft GJ, Valade E, Tan P.

PLoS Genet. 2013;9(9):e1003795. doi: 10.1371/journal.pgen.1003795. Epub 2013 Sep 12.

21.

Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.

Andreu N, Zelmer A, Sampson SL, Ikeh M, Bancroft GJ, Schaible UE, Wiles S, Robertson BD.

J Antimicrob Chemother. 2013 Sep;68(9):2118-27. doi: 10.1093/jac/dkt155. Epub 2013 Apr 30.

22.

Blockade of IL-10 signaling during bacillus Calmette-Guérin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-γ and IL-17 responses and increases protection to Mycobacterium tuberculosis infection.

Pitt JM, Stavropoulos E, Redford PS, Beebe AM, Bancroft GJ, Young DB, O'Garra A.

J Immunol. 2012 Oct 15;189(8):4079-87. doi: 10.4049/jimmunol.1201061. Epub 2012 Sep 12.

23.

Production of interleukin-27 by human neutrophils regulates their function during bacterial infection.

Rinchai D, Khaenam P, Kewcharoenwong C, Buddhisa S, Pankla R, Chaussabel D, Bancroft GJ, Lertmemongkolchai G.

Eur J Immunol. 2012 Dec;42(12):3280-90. doi: 10.1002/eji.201242526. Epub 2012 Oct 25.

24.

Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity.

Müller CM, Conejero L, Spink N, Wand ME, Bancroft GJ, Titball RW.

Infect Immun. 2012 Sep;80(9):3247-55. doi: 10.1128/IAI.00178-12. Epub 2012 Jul 9.

25.

A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging.

Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N, Robertson BD, Wiles S, Ward TH, Parish T, Ripoll J, Bancroft GJ, Schaible UE.

J Antimicrob Chemother. 2012 Aug;67(8):1948-60. doi: 10.1093/jac/dks161. Epub 2012 May 25.

26.

Development of vaccines against burkholderia pseudomallei.

Patel N, Conejero L, De Reynal M, Easton A, Bancroft GJ, Titball RW.

Front Microbiol. 2011 Sep 27;2:198. doi: 10.3389/fmicb.2011.00198. eCollection 2011.

27.

Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.

Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, Krieg AM, Titball RW, Bancroft GJ.

J Infect Dis. 2011 Aug 15;204(4):636-44. doi: 10.1093/infdis/jir301.

28.

Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis.

Conejero L, Patel N, de Reynal M, Oberdorf S, Prior J, Felgner PL, Titball RW, Salguero FJ, Bancroft GJ.

Am J Pathol. 2011 Jul;179(1):270-80. doi: 10.1016/j.ajpath.2011.03.031. Epub 2011 May 5.

29.

Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis.

Suwannasaen D, Mahawantung J, Chaowagul W, Limmathurotsakul D, Felgner PL, Davies H, Bancroft GJ, Titball RW, Lertmemongkolchai G.

J Infect Dis. 2011 Apr 1;203(7):1002-11. doi: 10.1093/infdis/jiq142. Epub 2011 Feb 7.

30.

CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis.

Chu KK, Tippayawat P, Walker NJ, Harding SV, Atkins HS, Maillere B, Bancroft GJ, Lertmemongkolchai G, Altmann DM.

Eur J Immunol. 2011 Jan;41(1):107-15. doi: 10.1002/eji.201040881. Epub 2010 Dec 3.

31.

Burkholderia pseudomallei proteins presented by monocyte-derived dendritic cells stimulate human memory T cells in vitro.

Tippayawat P, Pinsiri M, Rinchai D, Riyapa D, Romphruk A, Gan YH, Houghton RL, Felgner PL, Titball RW, Stevens MP, Galyov EE, Bancroft GJ, Lertmemongkolchai G.

Infect Immun. 2011 Jan;79(1):305-13. doi: 10.1128/IAI.00803-10. Epub 2010 Nov 1.

32.

Protective cellular responses to Burkholderia mallei infection.

Rowland CA, Lever MS, Griffin KF, Bancroft GJ, Lukaszewski RA.

Microbes Infect. 2010 Oct;12(11):846-53. doi: 10.1016/j.micinf.2010.05.012. Epub 2010 Jun 11.

PMID:
20542133
33.

Optimisation of bioluminescent reporters for use with mycobacteria.

Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S.

PLoS One. 2010 May 24;5(5):e10777. doi: 10.1371/journal.pone.0010777.

34.

Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung.

Redford PS, Boonstra A, Read S, Pitt J, Graham C, Stavropoulos E, Bancroft GJ, O'Garra A.

Eur J Immunol. 2010 Aug;40(8):2200-10. doi: 10.1002/eji.201040433.

35.

Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters.

Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T.

PLoS One. 2010 Mar 23;5(3):e9823. doi: 10.1371/journal.pone.0009823.

36.

Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis.

Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, Banchereau J, Lertmemongkolchai G, Chaussabel D.

Genome Biol. 2009;10(11):R127. doi: 10.1186/gb-2009-10-11-r127. Epub 2009 Nov 10.

37.

Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei.

Tippayawat P, Saenwongsa W, Mahawantung J, Suwannasaen D, Chetchotisakd P, Limmathurotsakul D, Peacock SJ, Felgner PL, Atkins HS, Titball RW, Bancroft GJ, Lertmemongkolchai G.

PLoS Negl Trop Dis. 2009;3(4):e407. doi: 10.1371/journal.pntd.0000407. Epub 2009 Apr 7.

38.

Burkholderia pseudomallei: animal models of infection.

Titball RW, Russell P, Cuccui J, Easton A, Haque A, Atkins T, Sarkar-Tyson M, Harley V, Wren B, Bancroft GJ.

Trans R Soc Trop Med Hyg. 2008 Dec;102 Suppl 1:S111-6. doi: 10.1016/S0035-9203(08)70026-9.

PMID:
19121670
39.

The case for hypervirulence through gene deletion in Mycobacterium tuberculosis.

ten Bokum AM, Movahedzadeh F, Frita R, Bancroft GJ, Stoker NG.

Trends Microbiol. 2008 Sep;16(9):436-41. doi: 10.1016/j.tim.2008.06.003. Epub 2008 Aug 11. Review.

PMID:
18701293
40.

Altered proteome in Burkholderia pseudomallei rpoE operon knockout mutant: insights into mechanisms of rpoE operon in stress tolerance, survival, and virulence.

Thongboonkerd V, Vanaporn M, Songtawee N, Kanlaya R, Sinchaikul S, Chen ST, Easton A, Chu K, Bancroft GJ, Korbsrisate S.

J Proteome Res. 2007 Apr;6(4):1334-41. Epub 2007 Mar 9.

PMID:
17346071
41.

Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis.

Cuccui J, Easton A, Chu KK, Bancroft GJ, Oyston PC, Titball RW, Wren BW.

Infect Immun. 2007 Mar;75(3):1186-95. Epub 2006 Dec 22.

42.

A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei.

Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ.

J Infect Dis. 2007 Jan 1;195(1):99-107. Epub 2006 Nov 21.

PMID:
17152013
43.

A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins.

Haque A, Chu K, Easton A, Stevens MP, Galyov EE, Atkins T, Titball R, Bancroft GJ.

J Infect Dis. 2006 Nov 1;194(9):1241-8. Epub 2006 Sep 25.

PMID:
17041850
44.

Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei.

Rowland CA, Lertmemongkolchai G, Bancroft A, Haque A, Lever MS, Griffin KF, Jackson MC, Nelson M, O'Garra A, Grencis R, Bancroft GJ, Lukaszewski RA.

Infect Immun. 2006 Sep;74(9):5333-40.

45.

Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection.

Haque A, Easton A, Smith D, O'Garra A, Van Rooijen N, Lertmemongkolchai G, Titball RW, Bancroft GJ.

J Infect Dis. 2006 Feb 1;193(3):370-9. Epub 2005 Dec 27.

PMID:
16388484
46.

Multinucleated giant cell formation and apoptosis in infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB.

Suparak S, Kespichayawattana W, Haque A, Easton A, Damnin S, Lertmemongkolchai G, Bancroft GJ, Korbsrisate S.

J Bacteriol. 2005 Sep;187(18):6556-60. No abstract available.

47.

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.

Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH.

J Clin Invest. 2005 Sep;115(9):2472-9. Epub 2005 Aug 18.

48.

Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis.

Stevens MP, Haque A, Atkins T, Hill J, Wood MW, Easton A, Nelson M, Underwood-Fowler C, Titball RW, Bancroft GJ, Galyov EE.

Microbiology. 2004 Aug;150(Pt 8):2669-76.

PMID:
15289563
49.

The Mycobacterium tuberculosis ino1 gene is essential for growth and virulence.

Movahedzadeh F, Smith DA, Norman RA, Dinadayala P, Murray-Rust J, Russell DG, Kendall SL, Rison SC, McAlister MS, Bancroft GJ, McDonald NQ, Daffe M, Av-Gay Y, Stoker NG.

Mol Microbiol. 2004 Feb;51(4):1003-14.

50.

Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis.

Parish T, Smith DA, Kendall S, Casali N, Bancroft GJ, Stoker NG.

Infect Immun. 2003 Mar;71(3):1134-40.

Supplemental Content

Loading ...
Support Center